Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-04-01
Study Completion Date
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the safety, efficacy and pharmacokinetic properties of Boya's IVIG preparation in participants with PID aged less than 60 years and more than 6 years.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase 3, open-label, prospective, single-group, multicenter study to evaluate the efficacy of IVIG in keeping the average number of serious bacterial infections to less than one per year. The safety and pharmacokinetics (PK) of the investigational product will also be assessed. Fifty male or female participants aged up to 60 years will be selected, with at least 20 participants aged between 06 and 17 years. During the study, at least 20 adult participants will be invited to make up the subgroups evaluating the pharmacokinetic parameters.
The main benefit of IVIG is to help the immune system respond to a wide range of infections, which are often correlated with high morbidity and mortality rates in individuals with PID, particularly in cases of CVID and XLA. In addition, a reduction in the use of medication and hospitalizations is expected, promoting an improvement in the quality of life of these patients.
IVIG therapy is generally safe, although unwanted effects are reported in a proportion ranging from 1% to 81% of patients or infusions, with an average incidence of 30% to 40% among patients and 5% to 15% among infusions. These effects can manifest themselves in varying degrees of intensity, ranging from mild to severe. They can occur immediately, during or shortly after the infusion, as well as late, appearing hours or even days after the procedure. Most adverse events are mild and immediate, occurring in the first few infusions, related to the infusion rate and quickly reversible.
Headache, fever, general malaise, flu-like symptoms, nausea, chills, fatigue, myalgia, low back pain, tachycardia, changes in blood pressure and erythroderma are the most common events. Serious reactions occur in less than 1% of applications and usually with the use of higher doses, indicated in autoimmune and inflammatory diseases.
Special care is needed in patients with comorbidities such as heart disease, nephropathy, liver disease, coagulation disorders (thrombophilia) and diabetes mellitus. In these patients, certain characteristics of IVIG should be assessed, such as the presence of sugars, osmolality, sodium, among others.
The main benefit of IVIG is to help the immune system respond to a wide range of infections, which are often correlated with high morbidity and mortality rates in individuals with PID, particularly in cases of CVID and XLA. In addition, a reduction in the use of medication and hospitalizations is expected, promoting an improvement in the quality of life of these patients.
IVIG therapy is generally safe, although unwanted effects are reported in a proportion ranging from 1% to 81% of patients or infusions, with an average incidence of 30% to 40% among patients and 5% to 15% among infusions. These effects can manifest themselves in varying degrees of intensity, ranging from mild to severe. They can occur immediately, during or shortly after the infusion, as well as late, appearing hours or even days after the procedure. Most adverse events are mild and immediate, occurring in the first few infusions, related to the infusion rate and quickly reversible.
Headache, fever, general malaise, flu-like symptoms, nausea, chills, fatigue, myalgia, low back pain, tachycardia, changes in blood pressure and erythroderma are the most common events. Serious reactions occur in less than 1% of applications and usually with the use of higher doses, indicated in autoimmune and inflammatory diseases.
Special care is needed in patients with comorbidities such as heart disease, nephropathy, liver disease, coagulation disorders (thrombophilia) and diabetes mellitus. In these patients, certain characteristics of IVIG should be assessed, such as the presence of sugars, osmolality, sodium, among others.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Immunodeficiency Disease
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
BOYA
IVIG
PID
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Patients with primary immunodeficiency will switch to Boya IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. IgG trough levels will be collected from all participants, at all visits. The remaining pharmacokinetic parameters will be measured between visits 4 and 5 in 20 adult participants, collecting additional blood samples.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
The trial will be open-label and single-arm. Therefore, there will be no randomization or blinding.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Boya IVIG
Patients with primary immunodeficiency will switch to Boya IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. The minimum IgG concentration will be measured in all participants at all visits. The other pharmacokinetic parameters will be measured between visits 4 and 5 in 20 adult participants by taking additional blood samples. An independent Safety Data Monitoring Committee (SDMC) will periodically monitor adverse events.
Group Type
EXPERIMENTAL
Boya IVIG
Intervention Type
BIOLOGICAL
The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:
* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;
* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Boya IVIG
The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:
* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;
* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
IVIG
BOYA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signature of written informed consent.
2. Men or women.
3. Age ≤ 60 years.
4. Diagnosis of PID disease (PID) with a reduction in antibody production due to:
1. Common variable immunodeficiency (CVID) as defined ESID/PAGID, OR
2. X-linked agammaglobulinemia (XLA) as defined by ESID/PAGID.
5. Receiving intravenous immunoglobulin replacement therapy at 21- or 28-day intervals at 300 to 600 mg/kg/month for a minimum of 2 months prior to study entry.
6. Absence of episodes of serious bacterial infections with prior use of IV immunoglobulin for at least 3 months prior to screening.
7. Negative pregnancy test (in female participants of childbearing potential); readiness to use reliable contraceptive methods throughout the study period.
8. Patients who have participated in a clinical study with another investigational IVIG may be included if they have a potential benefit in accordance with CNS Res. 251/1997.
9. Participants undergoing treatment with any subcutaneous or intramuscular immunoglobulin may be included by switching to IVIG therapy at the discretion of the investigator, considering the possible benefit to the participant.
2. Men or women.
3. Age ≤ 60 years.
4. Diagnosis of PID disease (PID) with a reduction in antibody production due to:
1. Common variable immunodeficiency (CVID) as defined ESID/PAGID, OR
2. X-linked agammaglobulinemia (XLA) as defined by ESID/PAGID.
5. Receiving intravenous immunoglobulin replacement therapy at 21- or 28-day intervals at 300 to 600 mg/kg/month for a minimum of 2 months prior to study entry.
6. Absence of episodes of serious bacterial infections with prior use of IV immunoglobulin for at least 3 months prior to screening.
7. Negative pregnancy test (in female participants of childbearing potential); readiness to use reliable contraceptive methods throughout the study period.
8. Patients who have participated in a clinical study with another investigational IVIG may be included if they have a potential benefit in accordance with CNS Res. 251/1997.
9. Participants undergoing treatment with any subcutaneous or intramuscular immunoglobulin may be included by switching to IVIG therapy at the discretion of the investigator, considering the possible benefit to the participant.
Exclusion Criteria
1. Known intolerance or hypersensitivity to immunoglobulins or components of the test article;
2. Any contraindications to the use of immunoglobulins;
3. Secondary immunodeficiency or conditions potentially causing secondary immunodeficiency such as chronic lymphoid leukemia, lymphoma, multiple myeloma, protein-losing enteropathies or nephropathies, and hypoalbuminemia;
4. Clinically relevant changes in the safety exams are defined as:
* Blood count
* Hb \< 10.5 g/dL
* Leukocytes \< 3,000 / mm3 or \>10,000 cells / mm3
* Absolute neutrophil count \< 1,000 cells/mm3;
* Coagulation
* TP and aPTT \> 2.5 x ULN
* Biochemistry
* glycated hemoglobin \> 6.5%
* total bilirubin and fractions, alkaline phosphatase, ALT, AST, GGT \> 2.5 x ULN
* creatinine above 3mg/dl or creatinine clearance \< 30mL/min
* Urine I.
* Leukocyturia \> 10,000 cells/mL
5. Any cancer either active or resolved within the last 12 months before screening;
6. Receiving any blood products (except intravenous immunoglobulins) during the last 3 months before screening;
7. Any febrile illness within 14 days before enrollment; Note: The patient may be rescreened after recovery.
8. History of thrombotic events (including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis) within 6 months before enrollment;
9. Previous use of live attenuated virus vaccines;
10. Selective deficiency of immunoglobulin A (IgA) or known antibodies to IgA;
11. Known drug or alcohol abuse;
12. The need to use other investigational drugs, systemic immunosuppressants, and any other immunoglobulins;
13. Pregnancy or lactation;
14. Inability to comply with the protocol activities;
15. PIDs other than CVID or X-linked agammaglobulinemia
16. Patients infected with HIV, HBV or HCV
17. Patients with AIDS, cystic fibrosis, or active hepatitis B or C.
18. Any other condition that, in the Investigator's opinion may increase the risk of participation in this study.
2. Any contraindications to the use of immunoglobulins;
3. Secondary immunodeficiency or conditions potentially causing secondary immunodeficiency such as chronic lymphoid leukemia, lymphoma, multiple myeloma, protein-losing enteropathies or nephropathies, and hypoalbuminemia;
4. Clinically relevant changes in the safety exams are defined as:
* Blood count
* Hb \< 10.5 g/dL
* Leukocytes \< 3,000 / mm3 or \>10,000 cells / mm3
* Absolute neutrophil count \< 1,000 cells/mm3;
* Coagulation
* TP and aPTT \> 2.5 x ULN
* Biochemistry
* glycated hemoglobin \> 6.5%
* total bilirubin and fractions, alkaline phosphatase, ALT, AST, GGT \> 2.5 x ULN
* creatinine above 3mg/dl or creatinine clearance \< 30mL/min
* Urine I.
* Leukocyturia \> 10,000 cells/mL
5. Any cancer either active or resolved within the last 12 months before screening;
6. Receiving any blood products (except intravenous immunoglobulins) during the last 3 months before screening;
7. Any febrile illness within 14 days before enrollment; Note: The patient may be rescreened after recovery.
8. History of thrombotic events (including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis) within 6 months before enrollment;
9. Previous use of live attenuated virus vaccines;
10. Selective deficiency of immunoglobulin A (IgA) or known antibodies to IgA;
11. Known drug or alcohol abuse;
12. The need to use other investigational drugs, systemic immunosuppressants, and any other immunoglobulins;
13. Pregnancy or lactation;
14. Inability to comply with the protocol activities;
15. PIDs other than CVID or X-linked agammaglobulinemia
16. Patients infected with HIV, HBV or HCV
17. Patients with AIDS, cystic fibrosis, or active hepatitis B or C.
18. Any other condition that, in the Investigator's opinion may increase the risk of participation in this study.
Minimum Eligible Age
6 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boya Bio Pharmaceutical Group Co Ltd
UNKNOWN
Sponsor Role
collaborator
Azidus Brasil
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luciana Ferrara
Role: STUDY_DIRECTOR
Azidus Brasil
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Goudouris ES, Rego Silva AM, Ouricuri AL, Grumach AS, Condino-Neto A, Costa-Carvalho BT, Prando CC, Kokron CM, Vasconcelos DM, Tavares FS, Silva Segundo GR, Barreto IC, Dorna MB, Barros MA, Forte WCN. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies. Einstein (Sao Paulo). 2017;15(1):1-16. doi: 10.1590/S1679-45082017AE3844.
Reference Type
BACKGROUND
Cordero E, Goycochea-Valdivia W, Mendez-Echevarria A, Allende LM, Alsina L, Bravo Garcia-Morato M, Gil-Herrera J, Gudiol C, Len-Abad O, Lopez-Medrano F, Moreno-Perez D, Munoz P, Olbrich P, Sanchez-Ramon S, Soler-Palacin P, Aguilera Cros C, Arostegui JI, Badell Serra I, Carbone J, Fortun J, Gonzalez-Granado LI, Lopez-Granados E, Lucena JM, Parody R, Ramakers J, Regueiro JR, Riviere JG, Roca-Oporto C, Rodriguez Pena R, Santos-Perez JL, Rodriguez-Gallego C, Neth O. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Nov;38(9):438-443. doi: 10.1016/j.eimc.2020.07.001. English, Spanish.
Reference Type
BACKGROUND
Bierry G, Boileau J, Barnig C, Gasser B, Korganow AS, Buy X, Jeung MY, Roy C, Gangi A. Thoracic manifestations of primary humoral immunodeficiency: a comprehensive review. Radiographics. 2009 Nov;29(7):1909-20. doi: 10.1148/rg.297095717.
Reference Type
BACKGROUND
Herriot R, Sewell WA. Antibody deficiency. J Clin Pathol. 2008 Sep;61(9):994-1000. doi: 10.1136/jcp.2007.051177.
Reference Type
BACKGROUND
BRUTON OC. Agammaglobulinemia. Pediatrics. 1952 Jun;9(6):722-8. No abstract available.
Reference Type
BACKGROUND
Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):23-33. doi: 10.1111/j.1365-2249.2009.04024.x.
Reference Type
BACKGROUND
Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH; Vivaglobin Study Group. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010 Jun 28;15(6):238-45. doi: 10.1186/2047-783x-15-6-238.
Reference Type
BACKGROUND
World Health Organization (2005) Recommendations for the production, control and regulation of human plasma for fractionation, Annex 4, TRS nº 941, pp. 69.
Reference Type
BACKGROUND
Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010 Jan;98(1):12-28. doi: 10.1111/j.1423-0410.2009.01226.x. Epub 2009 Jul 29.
Reference Type
BACKGROUND
Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993 Mar 27;341(8848):789-90. doi: 10.1016/0140-6736(93)90563-v.
Reference Type
BACKGROUND
Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996 May;104 Suppl 1:3-9.
Reference Type
BACKGROUND
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525-53. doi: 10.1016/j.jaci.2006.01.015.
Reference Type
BACKGROUND
Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, Hammarstrom L, Nonoyama S, Quinti I, Routes JM, Tang ML, Warnatz K. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59. doi: 10.1016/j.jaip.2015.07.025. Epub 2015 Nov 7.
Reference Type
BACKGROUND
Yazdani R, Habibi S, Sharifi L, Azizi G, Abolhassani H, Olbrich P, Aghamohammadi A. Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management. J Investig Allergol Clin Immunol. 2020;30(1):14-34. doi: 10.18176/jiaci.0388. Epub 2019 Feb 11.
Reference Type
BACKGROUND
Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002 Jun;109(6):1001-4. doi: 10.1067/mai.2002.124999.
Reference Type
BACKGROUND
Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, Chavoshzadeh Z, Jadid L, Rezaei N, Moin M. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006 Apr;39(2):114-20.
Reference Type
BACKGROUND
Salehzadeh M, Aghamohammadi A, Rezaei N. Evaluation of immunoglobulin levels and infection rate in patients with common variable immunodeficiency after immunoglobulin replacement therapy. J Microbiol Immunol Infect. 2010 Feb;43(1):11-7. doi: 10.1016/S1684-1182(10)60002-3. Epub 2010 Mar 29.
Reference Type
BACKGROUND
Suri D, Rawat A, Singh S. X-linked Agammaglobulinemia. Indian J Pediatr. 2016 Apr;83(4):331-7. doi: 10.1007/s12098-015-2024-8. Epub 2016 Feb 24.
Reference Type
BACKGROUND
Milito C, Pulvirenti F, Pesce AM, Digiulio MA, Pandolfi F, Visentini M, Quinti I. Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies. J Clin Immunol. 2014 Oct;34(7):813-9. doi: 10.1007/s10875-014-0081-9. Epub 2014 Jul 22.
Reference Type
BACKGROUND
Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, Trombetta AC, Visentini M, Martini H, Plebani A, Fiorilli M; IPINet Investigators. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011 Jun;31(3):315-22. doi: 10.1007/s10875-011-9511-0. Epub 2011 Mar 2.
Reference Type
BACKGROUND
Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol. 1999 Oct;118 Suppl 1(Suppl 1):1-28. doi: 10.1046/j.1365-2249.1999.00109.x. No abstract available.
Reference Type
BACKGROUND
EMA/CHMP/BPWP/94033/2007 rev. 4. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg), Sep,2020.
Reference Type
BACKGROUND
Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. Rockville, MD, pp. 17, Jun,2008.
Reference Type
BACKGROUND
Brasil, Resolução nº 251, de 07 de agosto de 1977. Disponível em; https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//resolucao-cns-251-97.pdf. Acesso em 25 de out de 2023
Reference Type
BACKGROUND
Mongkonsritragoon W, Srivastava R, Seth D, Navalpakam A, Poowuttikul P. Non-infectious Pulmonary Complications in Children with Primary Immunodeficiency. Clin Med Insights Pediatr. 2023 Sep 8;17:11795565231196431. doi: 10.1177/11795565231196431. eCollection 2023.
Reference Type
BACKGROUND
World Health Organization (2009). Conceptual Framework of the International Classification for Patient safety. World Health Organization, Patient Safety. Quem Press.
Reference Type
BACKGROUND
Brasil. Manual de orientação: pendências frequentes em protocolo de pesquisas. Disponível em: https://conselho.saude.gov.br/Web_comissoes/conep/aquivos/documentos/MANUAL_ORIENTACAO_PENDENCIAS_FREQUENTES_PROTOCOLOS_PESQUISA_CLINICA_V1.pdf. Acesso em: 26out2023
Reference Type
BACKGROUND
Harmonisation for better health (1998). Statitical Principles for Clinical Trials E9. Disponível em: Disponível em: https://database.ich.org/sites/default/files/E9_Guideline.pdf Acesso em: 01nov2023
Reference Type
BACKGROUND
Harmonisation for better health (1998). The Guideline Statistical Principles for Clinical Trials E9 (R1). Disponível em: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf Acesso em: 01nov2023
Reference Type
BACKGROUND
Conselho das Organizações Internacionais de Ciências Médicas (CIOMS) em colaboração com a Organização Mundial da Saúde (2016). Diretrizes éticas internacionais para pesquisas relacionadas a saúde envolvendo seres humanos. Disponível em: https://cioms.ch/wp-content/uploads/2018/11/CIOMS-final-Diretrizes-Eticas-Internacionais-Out18.pdf. Acesso em: 31out2023
Reference Type
BACKGROUND
Harmonisation for better health (2016). Guideline for Good Clinical Practice. Disponível em: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf Acesso em: 01nov2023
Reference Type
BACKGROUND
Organização Pan-Americana da Saúde (2005). Boas Práticas Clínicas: Documentos das Américas. Disponível em: https://www.gov.br/anvisa/ptbr/centraisdeconteudo/publicacoes/medicamentos/pesquisa-clinica/manuais-e-guias/documento-das-americas-boas-praticas-clinicas.pdf/view. Acesso em: 01out2023
Reference Type
BACKGROUND
Brasil (2018). Lei Geral de Proteção de Dados. 14ago2018. Disponível em: https://www.planalto.gov.br/ccivil_03/_ato2015-2018/2018/lei/L13709compilado.htm. Acessado em 09nov23.
Reference Type
BACKGROUND
Brasil (2008) Diretrizes Operacionais para o estabelecimento e o funcionamento de comitês de monitoramento de dados e segurança. Brasília, pp. 44.
Reference Type
BACKGROUND
Food and Drug Administration (2006). Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. Rockville, MD, pp. 38.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BoyaIVIG
Identifier Type: -
Identifier Source: org_study_id